OncoSec Medical to Present at the Sachs Cancer Bio Partnering Forum and Participate in a Panel Discussion on Immunotherapies and Cancer Vaccines
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its
advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy
to treat solid tumor cancers, announced that Punit Dhillon, President
and CEO, will present at the Sachs Cancer Bio Partnering Forum at the
Westin Copley Place in Boston, Massachusetts, on Tuesday, May 21, at
2:05 PM ET.
In addition, Mr. Dhillon will be participating in a panel discussion
titled “Immunotherapies & Cancer Vaccines” to be held on Tuesday, May
21, at 4:00 PM ET. The panel will be chaired by Florian Schodel, CEO,
Philimmune LLC, and Mara Goldstein, Senior Analyst, Cantor Fitzgerald.
About the Sachs Cancer Bio Partnering Forum
The Sachs Cancer Bio Partnering Forum is a two-day conference designed
to bring together thought leaders from cancer research institutes,
patient advocacy groups, pharma and biotech to facilitate partnering and
funding/investment. Approximately 300 delegates are expected. There will
be presentations by various research institutes, patient advocacy
groups, pharmaceutical companies on partnering and biotechs seeking
licensing/investment. For more information, visit: http://www.sachsforum.com/boston13/.
About OncoSec Medical Inc.
OncoSec Medical Inc. is a biopharmaceutical company developing its
advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy
to treat solid tumor cancers. ImmunoPulse and NeoPulse therapies address
an unmet medical need and represent a potential solution, for less
invasive and less expensive therapies that are able to minimize
detrimental effects resulting from currently available cancer treatments
such as surgery, systemic chemotherapy or immunotherapy and other
treatment alternatives. OncoSec Medical's core technology is based upon
its proprietary use of an electroporation platform to dramatically
enhance the delivery and uptake of a locally delivered DNA-based
immunocytokine (ImmunoPulse) or chemotherapeutic agent (NeoPulse).
Treatment of various solid cancers using these powerful and
targeted anti-cancer agents has demonstrated selective destruction of
cancerous cells while sparing healthy normal tissues during early and
late stage clinical trials. OncoSec's clinical programs include three
Phase II clinical trials for ImmunoPulse targeting lethal skin cancers.
More information is available at http://www.oncosec.com/.
This press release contains forward looking statements within the
meaning of the U.S. Private Securities Litigation Reform Act of 1995.
Any statements in this release that are not historical facts may be
considered such “forward looking statements.” Forward looking statements
are based on management's current preliminary expectations and are
subject to risks and uncertainties which may cause our results to differ
materially and adversely from the statements contained herein. Some of
the potential risks and uncertainties that could cause actual results to
differ from those predicted include our ability to raise additional
funding, our ability to acquire, develop or commercialize new products,
uncertainties inherent in pre-clinical studies and clinical trials,
unexpected new data, safety and technical issues, competition and market
conditions. These and additional risks and uncertainties are more fully
described in OncoSec Medical's filings with the Securities and Exchange
Commission. Undue reliance should not be placed on forward looking
statements which speak only as of the date they are made. OncoSec
Medical disclaims any obligation to update any forward looking
statements to reflect new information, events or circumstances after the
date they are made, or to reflect the occurrence of unanticipated events.
